TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7917930
Drug: 16 g
Normalized name: Maltsupex, 16 g/15 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 g of glutamine per day for 8 days
Study: 3140688
Drug: Flumazenil (Anexate)
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumazenil (Anexate) administered postoperatively in incremental doses up to 1 mg
Study: 3140688
Drug: Flumazenil (Anexate)
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumazenil (Anexate) administered postoperatively
Study: 18838750
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine sulphate 10 mg
Study: 18838750
Drug: Sodium diclofenac
Normalized name: Diclofenac Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium diclofenac suppository 100 mg
Study: 16652054
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM) and adherence support (AT)
Study: 12958329
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with perindopril (4 mg/d) and diuretic indapamide (as needed)
Study: 10980588
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (NA) 500 mg daily for 7 days
Study: 10980588
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (NA) 1 g daily for a further 7 days
Study: 1611830
Drug: Insulin Tolerance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin Tolerance Test (ITT) with 0.1 U kg‐1 body weight, human Actrapid insulin given as an IV bolus; KITT measured over the period 3-15 min.
Study: 1611830
Drug: Euglycaemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycaemic clamp with insulin infusion of 50 mU kg‐1 h‐1 for 120 min; M/I values derived from the clamp.
Study: 29301520
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg once daily for 6 weeks
Study: 20729538
Drug: DHEA (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (75 mg once a day before and during IVF treatment)
Study: 15714184
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine (10 mg of 0.5% hyperbaric bupivacaine)
Study: 10665626
Drug: Divalproex oral
Normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex oral loading (30 mg/kg/day on days 1 and 2, followed by 20 mg/kg/day on days 3‐10)
Study: 10665626
Drug: Divalproex nonloading
Normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex nonloading (starting dose of 250 mg t.i.d. on days 1 and 2, followed by standard dose titration for days 3 to 10)
Study: 10665626
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (starting dose of 300 mg t.i.d., followed by standard dose titration for days 3 to 10)
Study: 8889672
Drug: Intravenous buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous buprenorphine (1.2 mg)
Study: 8889672
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine (4.0 mg)
Study: 8889672
Drug: Buccal buprenorphine
Normalized name: buprenorphine Buccal Film
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buccal buprenorphine (4.0 mg)
Study: 22120044
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg cocoa flavanols
Study: 22120044
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg cocoa flavanols
Study: 12883399
Drug: Midazolam administered
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam administered extracorporeally (into the circuit)
Study: 12883399
Drug: Midazolam administered
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam administered via central or peripheral access
Study: 7651559
Drug: Domperidone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (3 x 20 mg daily)
Study: 7651559
Drug: Ondansetron (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (3 x 8 mg daily)
Study: 2759694
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein milk (3.1 g/100 ml)
Study: 31743193
Drug: LIA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIA with 2.5 mL/kg of 0.2% ropivacaine
Study: 28844191
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg amoxicillin plus 500 mg metronidazole, three times daily for 7 days during the first non-surgical phase (T1)
Study: 28844191
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg amoxicillin plus 500 mg metronidazole, three times daily for 7 days during the second surgical phase (T2)
Study: 28844191
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of Parvimonas micra before therapy
Study: 22303705
Drug: Shenfu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu Injection (SI) 200 mL (50 mL SI in 200 mL normal saline)
Study: 22303705
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (200 mL normal saline)
Study: 22303705
Drug: Shenfu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu Injection (SI)
Study: 16567436
Drug: Post-tamoxifen discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-tamoxifen discontinuation
Study: 10912888
Drug: rhEPO (5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO (5,000 U, 3 times weekly for 4 weeks)
Study: 8826493
Drug: Control: lumbar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: lumbar subcutaneous injection of 3 ml of 0.5% bupivacaine
Study: 27930518
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of MSC transplantation and butylphthalide
Study: 20066671
Drug: Escitalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram treatment for 5 weeks
Study: 20066671
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment) for 1 week
Study: 15881486
Drug: oxycodone/acetaminophen 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxycodone/acetaminophen 10 mg/650 mg
Study: 15881486
Drug: codeine/acetaminophen 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: codeine/acetaminophen 60 mg/600 mg
Study: 2183939
Drug: Sucralfate 2
Normalized name: sucralfate 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 2 gm twice daily
Study: 377081
Drug: Ticrynafen 500
Normalized name: Ticrynafen
DrugBank: Tienilic acid (DB04831)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticrynafen 500 mg once daily
Study: 377081
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 or 100 mg
Study: 25286684
Drug: Reinforcing Qi
Normalized name: San Qi Root
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforcing Qi and Activating Blood treatment (Yu‐Ping‐Feng capsules and Fu‐Fang‐Dan‐Shen tablets for 3 months)
Study: 25286684
Drug: Reinforcing Qi
Normalized name: San Qi Root
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforcing Qi and Activating Blood treatment
Study: 17202548
Drug: Brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive behavioral therapy (N=79)
Study: 3595695
Drug: Amiodarone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (3 X 400 mg daily for 3 days) plus Methimazole (3 X 20 mg daily for 10 days)
Study: 3595695
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus Methimazole (3 X 20 mg daily for 10 days)
Study: 24757229
Drug: Automated predictive
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated predictive low glucose pump suspension system
Study: 24757229
Drug: No pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pump suspension (control)
Study: 24757229
Drug: Pump suspension
Normalized name: INTESTINAL PUMP SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pump suspension exceeding 2 hours
Study: 24757229
Drug: Automated pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated pump suspension system
Study: 15854139
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g intravenous ascorbic acid
Study: 15328062
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH infusion (10 microg/kg, 6‐min square wave pulse)
Study: 9496559
Drug: Octreotide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (50 mcg)
Study: 3064919
Drug: Nimodipine 40
Normalized name: nimodipine 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 40 mg three times a day
Study: 30242962
Drug: NYX-2925 (50-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: NYX-2925 (50-1200 mg single-ascending dose and 150-900 mg multiple-ascending dose)
Study: 26580240
Drug: Sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25 mg three times a day for 3 months
Study: 25189490
Drug: ACE-inhibitor perindopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-inhibitor perindopril
Study: 11561868
Drug: Oral proteolytic
Normalized name: PROTEOLYTIC ENZYME
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral proteolytic enzyme preparation (enzyme tablets t.i.d. starting 3 days prior to radiation therapy and continuing up to 5 days after completion)
Study: 3717115
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (lactulose or neomycin)
Study: 28061543
Drug: GTDS (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTDS (transdermal granisetron patch, 7 days)
Study: 28061543
Drug: Oral granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral granisetron (2 mg/day, ≥2 days)
Study: 28061543
Drug: GTDS and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTDS and Oral granisetron
Study: 25499944
Drug: 220.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 220.5 mg of cis-palmitoleic acid once per day for 30 days
Study: 25499944
Drug: Placebo (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1000 mg of medium chain triglycerides) once per day for 30 days
Study: 18023435
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy for low sexual desire
Study: 12878918
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Naltrexone and Acamprosate
Study: 12878918
Drug: CBI alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBI alone without pills
Study: 8952583
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg oral dose)
Study: 7259838
Drug: Single alkylating
Normalized name: petroleum alkylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single alkylating agent chemotherapy
Study: 7259838
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with cyclophosphamide, vincristine, and prednisone (CVP)
Study: 7259838
Drug: Fractionated whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated whole body irradiation followed by low dose involved field irradiation
Study: 31973700
Drug: Levobupivacaine/morphine (LM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine/morphine (LM)
Study: 22142548
Drug: Post-paracentesis intravenous
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-paracentesis intravenous nutritional support with a balanced oral diet and a late-evening protein snack (Group A)
Study: 22142548
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional protocol without parenteral support (Group B)
Study: 19000028
Drug: DHEA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA therapy
Study: 17208951
Drug: DHEA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA therapy in women with adrenal insufficiency
Study: 8601041
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mannitol (50 g) and albumin (75 g) in the pump prime
Study: 2632375
Drug: Antianxiety drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antianxiety drug
Study: 4925514
Drug: Antimalarials
Normalized name: ANTIMALARIALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimalarials
Study: 31980899
Drug: Body-oriented resilience
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body-oriented resilience therapy (BEATVIC)
Study: 20537501
Drug: Glutamine group
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine group (l‐glutamine 0.4g/[kg d])
Study: 18544001
Drug: Oral voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral voriconazole (200 mg single dose)
Study: 18544001
Drug: Intravenous voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous voriconazole solubilized with SBECD (6 mg/kg twice daily on day 1, then 3 mg/kg twice daily from days 2-6, followed by 3 mg/kg on day 7)
Study: 18544001
Drug: Intravenous voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous voriconazole solubilized with SBECD
Study: 15752161
Drug: Desmopressin (DDAVP)
Normalized name: desmopressin Injection [DDAVP]
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin (DDAVP) infusion followed by platelet concentrates (PCs)
Study: 1929272
Drug: Norfloxacin 200
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norfloxacin 200 mg daily
Study: 1929272
Drug: Nitrofurantoin 50
Normalized name: nitrofurantoin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin 50 mg daily
Study: 6800439
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin with sodium glycocholate
Study: 17449497
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin
Study: 24442886
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intravenous zoledronate
Study: 22435747
Drug: G+P (Granulocyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: G+P (Granulocyte colony-stimulating factor with plerixafor)
Study: 22435747
Drug: G-CSF (Granulocyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (Granulocyte colony-stimulating factor)
Study: 18981719
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta 10,000 IU thrice weekly and oral iron starting 10-15 days before treatment
Study: 7501332
Drug: Vaginal PGE2
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vaginal PGE2 gel (2 mg)
Study: 7501332
Drug: Vaginal PGE2
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vaginal PGE2 tablet (3 mg)
Study: 2169703
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and cholecalciferol supplementation (1000 mg Ca/d and 1000 IU cholecalciferol/d)
Study: 7214297
Drug: BCG immunotherapy
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG immunotherapy for periods of 9.4 +/- 1.7 months
Study: 7214297
Drug: No BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No BCG immunotherapy (control group)
Study: 28327694
Drug: Both SurfLink
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both SurfLink and control implants
Study: 26318757
Drug: Goal-directed haemodynamic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed haemodynamic therapy using oesophageal Doppler during surgery
Study: 24371255
Drug: A(H3N2) viruses
Normalized name: Haemagglutinin-strain A(H3N2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A(H3N2) viruses classified as homologous to the vaccine strains based on HA1 domain nucleic acid sequence
Study: 24371255
Drug: A(H1N1) viruses
Normalized name: Haemagglutinin-strain A(H1N1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A(H1N1) viruses classified as homologous to the vaccine strains based on HA1 domain nucleic acid sequence
Study: 20011757
Drug: Fluoride-containing dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride-containing dentifrice (NaF dentifrice) on a toothbrush for 60 s twice a day
Study: 20011757
Drug: Unwaxed dental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unwaxed dental floss twice a day
Study: 20011757
Drug: Waxed dental
Normalized name: Candelilla Wax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waxed dental floss twice a day in every interproximal space
Study: 20011757
Drug: Drinking water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking water rinsing twice a day for 60 s
Study: 17142825
Drug: 5 u
Normalized name: vitamin E 5 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 u of oxytocin as a bolus injection
Study: 17142825
Drug: 5 u
Normalized name: vitamin E 5 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 u of oxytocin as an infusion over 5 min
Study: 23759039
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (bolus and infusion)
Study: 15107384
Drug: Rapid dosing
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid dosing regimen (10 mg over 30 seconds, repeated once after three minutes if pain score remained above three)
Study: 15107384
Drug: Cautious dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cautious dosing regimen (5 mg over two minutes, repeated at three minute intervals if pain score remained above three to a maximum dose of 20 mg)
Study: 15107384
Drug: Rapid dosing
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid dosing regimen
Study: 15107384
Drug: Cautious dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cautious dosing regimen
Study: 9630259
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (treatment for 4 months)
Study: 9630259
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (4 months without treatment followed by 4 months of treatment)
Study: 8001718
Drug: Maltitol solutions
Normalized name: Maltitol
DrugBank: Maltitol (DB16867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltitol solutions
Study: 23821328
Drug: CarboRT (carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CarboRT (carboplatin 100 mg/m2)
Study: 23821328
Drug: CisRT (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CisRT (cisplatin 40 mg/m2)
Study: 14751362
Drug: Chemotherapy (estramustine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (estramustine 140 mg three times daily and etoposide 100 mg orally for 21 days)
Study: 14751362
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of somatostatin analog (lanreotide 30 mg intramuscularly every 14 days) and dexamethasone (4 mg tapered to 1 mg)
Study: 11105738
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of fluoxetine daily
Study: 11599647
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of fluoxetine weekly
Study: 15613168
Drug: Desipramine 75
Normalized name: desipramine 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine 75 mg
Study: 2974255
Drug: Atracurium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium administered by fast-flowing crystalloid infusion in the antecubital fossa
Study: 2974255
Drug: Atracurium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium administered by winged needle in the antecubital fossa with flushing after thiopentone
Study: 2974255
Drug: Atracurium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium administered by winged needle in the antecubital fossa without flushing
Study: 2974255
Drug: Atracurium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium administered by winged needle in the dorsum of the hand without flushing
Study: 2974255
Drug: Atracurium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium administered by fast-flowing crystalloid infusion in the antecubital fossa (subgroup of patients with drug allergy)
Study: 2974255
Drug: Atracurium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium administered by fast-flowing crystalloid infusion in the antecubital fossa (subgroup of patients aged over 70 years)
Study: 5328328
Drug: quinethazone 50
Normalized name: quinethazone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: quinethazone 50 mg
Study: 5328328
Drug: chlorothiazide 500
Normalized name: chlorothiazide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: chlorothiazide 500 mg